A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics

Yoshifumi Takei, Kenji Kadomatsu, Yukio Yuzawa, Seiichi Matsuo, Takashi Muramatsu

Cancer Research · 2004 · 381 citations · 16 references

DOIFull text

Open access

Concepts

TL;DR

VEGF is essential for embryonic angiogenesis and for pathological angiogenesis in diseases such as cancer. The study aimed to develop a novel VEGF blockade system via RNA interference. The system delivers siRNA targeting VEGF with atelocollagen to stabilize and efficiently transfect tumors. siRNA targeting VEGF nearly abolished VEGF secretion in PC‑3 cells and, when delivered with atelocollagen, markedly reduced tumor angiogenesis and growth in a PC‑3 xenograft model.

Abstract

Abstract Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.

References

16